• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

IDH 野生型胶质母细胞瘤的最新进展。

Updates in IDH-Wildtype Glioblastoma.

机构信息

Division of Neurology, Department of Medicine, Faculty of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.

出版信息

Neurotherapeutics. 2022 Oct;19(6):1705-1723. doi: 10.1007/s13311-022-01251-6. Epub 2022 May 31.

DOI:10.1007/s13311-022-01251-6
PMID:35641844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9154038/
Abstract

Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel therapies in IDH-wildtype GBM will be discussed.

摘要

胶质母细胞瘤是最具侵袭性的原发性脑肿瘤，预后较差。尽管治疗仍未有突破，但 2021 年 WHO CNS5 分类进一步强调了分子特征在诊断中的重要性。本文就 IDH 野生型胶质母细胞瘤的现有和新型治疗方法进行综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93cb/9723058/946866ebaaae/13311_2022_1251_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93cb/9723058/08f81d80d3b7/13311_2022_1251_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93cb/9723058/946866ebaaae/13311_2022_1251_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93cb/9723058/08f81d80d3b7/13311_2022_1251_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93cb/9723058/946866ebaaae/13311_2022_1251_Fig2_HTML.jpg

相似文献

1
Updates in IDH-Wildtype Glioblastoma.IDH 野生型胶质母细胞瘤的最新进展。
Neurotherapeutics. 2022 Oct;19(6):1705-1723. doi: 10.1007/s13311-022-01251-6. Epub 2022 May 31.
2
The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.异柠檬酸脱氢酶突变在接受同源治疗的间变性星形细胞瘤和胶质母细胞瘤患者中的预后作用。
Acta Neuropathol Commun. 2019 Oct 17;7(1):156. doi: 10.1186/s40478-019-0817-0.
3
Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.异柠檬酸脱氢酶（IDH）野生型脑胶质瘤的治疗进展。
Curr Neurol Neurosci Rep. 2023 Jun;23(6):263-276. doi: 10.1007/s11910-023-01268-0. Epub 2023 May 8.
4
Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases.基因改变在鉴别 IDH 野生型胶质母细胞瘤与低级别胶质瘤中的诊断效用：来自 479 例病例的下一代测序分析的见解。
Brain Pathol. 2024 Sep;34(5):e13234. doi: 10.1111/bpa.13234. Epub 2024 Jan 12.
5
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.前瞻性基于基因组的“早期/进展期”和“采样不足”IDH 野生型胶质母细胞瘤的识别可改善临床结局。
Neuro Oncol. 2022 Oct 3;24(10):1749-1762. doi: 10.1093/neuonc/noac089.
6
Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.替莫唑胺诱导的中性粒细胞减少症在胶质母细胞瘤异柠檬酸脱氢酶野生型患者中的预后重要性
Neurosurg Rev. 2018 Apr;41(2):621-628. doi: 10.1007/s10143-017-0903-3. Epub 2017 Sep 9.
7
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).IDH 野生型胶质母细胞瘤的长期生存：来自 EORTC 1419 肿瘤基金研究协作组的首次结果。
Eur J Cancer. 2023 Aug;189:112913. doi: 10.1016/j.ejca.2023.05.002. Epub 2023 May 8.
8
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.胶质母细胞瘤中的诊断和治疗生物标志物：现状与未来展望
Biomed Res Int. 2017;2017:8013575. doi: 10.1155/2017/8013575. Epub 2017 Feb 20.
9
TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.端粒酶逆转录酶（TERT）启动子突变状态对于诊断具有胶质母细胞瘤分子特征的异柠檬酸脱氢酶（IDH）野生型弥漫性星形细胞胶质瘤而言是必要且充分的。
Acta Neuropathol. 2021 Aug;142(2):323-338. doi: 10.1007/s00401-021-02337-9. Epub 2021 Jun 20.
10
Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.通过常规磁共振成像表现鉴别伴有和不伴有异柠檬酸脱氢酶基因突变的胶质母细胞瘤。
J Clin Neurosci. 2020 Jun;76:140-144. doi: 10.1016/j.jocn.2020.04.016. Epub 2020 Apr 11.

引用本文的文献

1
Glioblastoma: A Multidisciplinary Approach to Its Pathophysiology, Treatment, and Innovative Therapeutic Strategies.胶质母细胞瘤：关于其病理生理学、治疗及创新治疗策略的多学科方法
Biomedicines. 2025 Aug 2;13(8):1882. doi: 10.3390/biomedicines13081882.
2
Interpretable artificial intelligence based determination of glioma IDH mutation status directly from histology slides.基于可解释人工智能直接从组织学切片确定胶质瘤异柠檬酸脱氢酶（IDH）突变状态。
Neurooncol Adv. 2025 Jul 11;7(1):vdaf140. doi: 10.1093/noajnl/vdaf140. eCollection 2025 Jan-Dec.
3
Integrating Radiogenomics and Machine Learning in Musculoskeletal Oncology Care.

本文引用的文献

1
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.NRG Oncology/RTOG1205：贝伐珠单抗联合再放疗与贝伐珠单抗单药治疗复发性胶质母细胞瘤的随机 II 期试验。
J Clin Oncol. 2023 Feb 20;41(6):1285-1295. doi: 10.1200/JCO.22.00164. Epub 2022 Oct 19.
2
Advances in local therapy for glioblastoma - taking the fight to the tumour.胶质母细胞瘤的局部治疗进展——向肿瘤发起攻击。
Nat Rev Neurol. 2022 Apr;18(4):221-236. doi: 10.1038/s41582-022-00621-0. Epub 2022 Mar 11.
3
Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI.
将放射基因组学与机器学习整合于肌肉骨骼肿瘤护理中。
Diagnostics (Basel). 2025 May 29;15(11):1377. doi: 10.3390/diagnostics15111377.
4
Construction and validation of a prognostic nomogram model integrating machine learning-pathomics and clinical features in IDH-wildtype glioblastoma.整合机器学习-病理组学和临床特征的IDH野生型胶质母细胞瘤预后列线图模型的构建与验证
J Transl Med. 2025 Jun 3;23(1):618. doi: 10.1186/s12967-025-06482-7.
5
Twenty-five years of WWOX insight in cancer: a treasure trove of knowledge.WWOX在癌症研究领域的25年洞察：知识宝库
Funct Integr Genomics. 2025 May 6;25(1):100. doi: 10.1007/s10142-025-01601-5.
6
Maximum Resection of Noncontrast-enhanced Tumor at MRI Is a Favorable Prognostic Factor in IDH Wild-Type Glioblastoma.磁共振成像（MRI）上非强化肿瘤的最大程度切除是异柠檬酸脱氢酶（IDH）野生型胶质母细胞瘤的一个有利预后因素。
Radiology. 2025 May;315(2):e241393. doi: 10.1148/radiol.241393.
7
SERPINH1 and CTSZ are Key Markers of Glioma Angiogenesis.丝氨酸蛋白酶抑制剂H1（SERPINH1）和组织蛋白酶Z（CTSZ）是胶质瘤血管生成的关键标志物。
J Mol Neurosci. 2025 Apr 21;75(2):51. doi: 10.1007/s12031-025-02349-0.
8
Anti-miRNA- 155 - 5p enhances the cytotoxic efficacy of temozolomide in brain cancer stem cells.抗微小RNA-155-5p增强替莫唑胺对脑癌干细胞的细胞毒性作用。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 11. doi: 10.1007/s00210-025-04135-6.
9
Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her care.病例报告：一名胶质母细胞瘤长期存活患者，作为其治疗的一部分，接受了两个疗程的大分割放疗。
Front Oncol. 2025 Feb 4;15:1501466. doi: 10.3389/fonc.2025.1501466. eCollection 2025.
10
Investigating the relevance of nucleotide metabolism in the prognosis of glioblastoma through bioinformatics models.通过生物信息学模型研究核苷酸代谢在胶质母细胞瘤预后中的相关性。
Sci Rep. 2025 Feb 13;15(1):5363. doi: 10.1038/s41598-025-88970-w.
使用多参数生理和代谢 MRI 对人脑胶质瘤进行肿瘤异质性可视化和异柠檬酸脱氢酶突变状态预测。
Sci Rep. 2022 Jan 20;12(1):1078. doi: 10.1038/s41598-022-05077-2.
4
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.儿童种系 DNA 复制修复缺陷对 PD-1 抑制反应的基因组预测因子。
Nat Med. 2022 Jan;28(1):125-135. doi: 10.1038/s41591-021-01581-6. Epub 2022 Jan 6.
5
Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.使用相对脑血容量对 IDH 野生型胶质母细胞瘤进行微血管局部检测：一种用于星形细胞瘤 4 级分类的影像学标志物。
BMC Cancer. 2022 Jan 6;22(1):40. doi: 10.1186/s12885-021-09117-4.
6
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.IDH 野生型胶质母细胞瘤中靶向二代测序检测的临床应用对治疗决策的影响。
Neuro Oncol. 2022 Jul 1;24(7):1140-1149. doi: 10.1093/neuonc/noab282.
7
Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models.在患者来源的异种移植临床前模型中，优化新型微管靶向药物利沙万布林与胶质母细胞瘤标准治疗方案的有效组合。
Neuro Oncol. 2022 Mar 12;24(3):396-397. doi: 10.1093/neuonc/noab278.
8
Dabrafenib plus trametinib in patients with BRAF-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.达拉非尼联合曲美替尼治疗 BRAF 突变型低级别和高级别胶质瘤患者（ROAR）：一项多中心、开放标签、单臂、2 期、篮子试验。
Lancet Oncol. 2022 Jan;23(1):53-64. doi: 10.1016/S1470-2045(21)00578-7. Epub 2021 Nov 24.
9
Disparities and Inequities Among Patients with Central Nervous System Tumor.中枢神经系统肿瘤患者的差异和不平等。
Hematol Oncol Clin North Am. 2022 Feb;36(1):e1-e8. doi: 10.1016/j.hoc.2021.10.002.
10
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.用一种可穿透血脑屏障的再利用药物靶向神经胶质瘤信号和代谢。
Cell Rep. 2021 Nov 2;37(5):109957. doi: 10.1016/j.celrep.2021.109957.